Announcements Trials
Browse Landscape

Phase

Phase 1 33Phase 2 25Phase 1/2 15Phase 3 13Phase NA 7Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 15Neoplasm Metastasis 13Squamous Cell Carcinoma of Head and Neck 11Neoplasms 11Prostatic Neoplasms 10Breast Neoplasms 9Recurrence 7Ovarian Neoplasms 7Myasthenia Gravis 7Lung Neoplasms 7Leukemia, Myeloid, Acute 7Stomach Neoplasms 6Head and Neck Neoplasms 6Colorectal Neoplasms 6Lymphoma, Large B-Cell, Diffuse 5Fatigue 5Pancreatic Neoplasms 4Oropharyngeal Neoplasms 4Melanoma 4Fallopian Tube Neoplasms 4Colonic Neoplasms 4Urinary Bladder Neoplasms 3Rectal Neoplasms 3Peritoneal Neoplasms 3Mouth Neoplasms 3Glioblastoma 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3Anorexia 3Adenocarcinoma Of Esophagus 3

Interventions

Gemcitabine 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Carcinoma, Transitional Cell × 90 days × Clear all
NCT07129993 2026-05-14

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Daiichi Sankyo

Phase 2/3 Recruiting
630 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡